P. Leichner

发表

Accuracy of In‐Vivo Assessment of Prostatic Volume by MRI and Transrectal Ultrasonography

C M Tempany, C. Tempany, A. Rahmouni, 1992, Journal of computer assisted tomography.

A unified approach to photon and beta particle dosimetry.

P. Leichner, 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Conversion by new treatment modalities of nonresectable to resectable hepatocellular cancer.

E. Fishman, S. Order, J. Sitzmann, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of indium-111- and yttrium-90-labeled linker-immunoconjugates in nude mice and dogs.

J. Williams, P. Leichner, H. Vriesendorp, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial.

James R. Anderson, M. Tempero, D. Colcher, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium-90 and iodine-131 radioimmunoglobulin therapy of an experimental human hepatoma.

B. Wessels, T. H. Nguyen, L. Dillehay, 1989, Cancer research.

Antiferritin IgG antibody for isotopic cancer therapy.

S. Order, P. Leichner, J. Klein, 1981, Oncology.

Comparative tumor dose from 131I-labeled polyclonal anti-ferritin, anti-AFP, and anti-CEA in primary liver cancers.

D. Ettinger, E. Fishman, S. Siegelman, 1984, Cancer drug delivery.

90Yttrium antiferritin--a new therapeutic radiolabeled antibody.

D. Carlo, C. Lollo, S. Order, 1986, International journal of radiation oncology, biology, physics.

Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry.

J. B. Garrison, D. Ettinger, R. E. Jenkins, 1981, International journal of radiation oncology, biology, physics.

Radiolabeled antibodies: results and potential in cancer therapy.

S. Order, P. Leichner, J. Klein, 1990, Cancer research.

Patient-specific dosimetry of indium-111- and yttrium-90-labeled monoclonal antibody CC49.

W. Hawkins, M. Tempero, J. Baranowska-Kortylewicz, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Tumor dosimetry in radioimmunotherapy: methods of calculation for beta particles.

P. Leichner, C. Kwok, 1993, Medical physics.

Preclinical evaluation of intravenously administered 111In- and 90Y-labeled B72.3 immunoconjugate (GYK-DTPA) in beagle dogs.

J. Williams, Y. Shao, P. Leichner, 1993, Nuclear medicine and biology.

Phase I-II study of radiolabeled antibody integrated in the treatment of primary hepatic malignancies.

D. Ettinger, S. Siegelman, P. Alderson, 1979, International journal of radiation oncology, biology, physics.

Use of isotopic immunoglobulin in therapy.

D. Ettinger, S. Siegelman, P. Alderson, 1980, Cancer research.

Phase I-II study of isotopic immunoglobulin therapy for primary liver cancer.

D. Ettinger, M. Wharam, S. Order, 1982, Cancer treatment reports.

CT Volumetrics of Primary Liver Cancers

E. Fishman, S. Siegelman, W. Hawkins, 1986, Journal of computer assisted tomography.

Dosimetry of 131I-labeled antiferritin in hepatoma: specific activities in the tumor and liver.

D. Ettinger, S. Siegelman, S. Order, 1983, Cancer treatment reports.

Polyclonal 90Yttrium labeled antiferritin for refractory Hodgkin's disease.

S. Order, P. Leichner, J. Klein, 1989, International journal of radiation oncology, biology, physics.

Multi-modality treatment of primary nonresectable intrahepatic cholangiocarcinoma with 131I anti-CEA--a Radiation Therapy Oncology Group Study.

D. Ettinger, E. Fishman, S. Siegelman, 1987, International journal of radiation oncology, biology, physics.

Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01.

S. Order, P. Leichner, J. Klein, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Iodine 131 antiferritin, a new treatment modality in hepatoma: a Radiation Therapy Oncology Group study.

D. Ettinger, E. Fishman, E. Fishman, 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yttrium 90-labeled antiferritin followed by high-dose chemotherapy and autologous bone marrow transplantation for poor-prognosis Hodgkin's disease.

J. Armitage, P. Bierman, J. Vose, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dosimetry and treatment planning for 90Y-labeled antiferritin in hepatoma.

W. Hawkins, S. Order, T. Frenkel, 1988, International journal of radiation oncology, biology, physics.

Selection of reagents for human radioimmunotherapy.

O. Onyekwere, J. Williams, Y. Shao, 1992, International journal of radiation oncology, biology, physics.

Radiocolloids in the treatment of ovarian cancer.

P. Leichner, G. Vogelsang, N. Rosenshein, 1979, Obstetrical & gynecological survey.

Effects of injection volume on the tissue dose, dose rate, and therapeutic potential intraperitoneal 32p.

P. Leichner, R. Durand, S. A. Cash, 1981, Radiology.

Two- and three-body collision coefficients for Xe( 3 P 1 ) and Xe( 3 P 2 ) atoms and radiative lifetime of the Xe 2 (1 u ) molecule

K. F. Palmer, P. Leichner, J. D. Cook, 1976 .

194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study.

E. Fishman, S. Leibel, C. Guse, 1989, International journal of radiation oncology, biology, physics.

Induction of high grade astrocytoma (HGA) by protons: molecular mechanisms and RBE considerations.

K. Hardy, J. C. Mitchell, A. Cox, 1994, Advances in space research : the official journal of the Committee on Space Research.

Radiolabeled antibody in the treatment of primary and metastatic liver malignancies.

D. Ettinger, S. Leibel, S. Order, 1986, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Selective tumor localization in experimental hepatoma by radiolabeled antiferritin antibody.

S. Order, P. Leichner, J. Klein, 1983, International journal of radiation oncology, biology, physics.

Time dependence of the vacuum-ultraviolet emissions in krypton excited by 250-KeV electrons

P. Leichner, Robin J. Ericson, 1974 .

Dosimetry and treatment planning in radioimmunotherapy.

B. Wessels, W. Hawkins, S. Order, 1990, Frontiers of radiation therapy and oncology.

Prognostic factors in unresectable hepatocellular cancer: Radiation Therapy Oncology Group Study 83-01.

S. Leibel, C. Guse, S. Asbell, 1991, International journal of radiation oncology, biology, physics.

Multimodality treatment of patients with advanced ovarian carcinoma.

D. Ettinger, S. Order, P. Leichner, 1982, International journal of radiation oncology, biology, physics.

A randomized prospective trial comparing full dose chemotherapy to 131I antiferritin: an RTOG study.

D. Ettinger, S. Leibel, T. Pajak, 1991, International journal of radiation oncology, biology, physics.

Skeletal metastases from hepatoma: frequency, distribution, and radiographic features.

E. Fishman, D. Magid, S. Siegelman, 1986, Radiology.

Survival of patients with resistant Hodgkin's disease after polyclonal yttrium 90-labeled antiferritin treatment.

P. Leichner, J. Klein, H. Vriesendorp, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current status of radioimmunoglobulins in the treatment of human malignancy.

S. Order, P. Leichner, T. Klein, 1989, Oncology.

A model system that predicts effective half-life for radiolabeled antibody therapy.

M. Ling, S. Order, P. Leichner, 1985, International journal of radiation oncology, biology, physics.

High-dose therapy with 90Yttrium-labeled monoclonal antibody CC49: a phase I trial.

James R. Anderson, J. Schlom, M. Tempero, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Tumor Localization of Radio-Labeled Antibodies

D. Ettinger, R. Jewkes, M. Forni, 1980 .

Variable low dose rate irradiation (131I-anti-CEA) and integrated low dose chemotherapy in the treatment of nonresectable primary intrahepatic cholangiocarcinoma.

D. Ettinger, E. Fishman, S. Order, 1991, International journal of radiation oncology, biology, physics.

Hepatoma: model for radiolabeled antibody in cancer treatment.

S. Order, P. Leichner, J. Klein, 1987, NCI monographs : a publication of the National Cancer Institute.

Distribution and tissue dose of intraperitoneally administered radioactive chromic phosphate (32P) in New Zealand white rabbits.

S. Leibel, S. Order, P. Leichner, 1980, Radiology.

Quantitative SPECT for indium-111-labeled antibodies in the livers of beagle dogs.

W. Hawkins, P. Leichner, J. Klein, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Multimodality cisplatin treatment in nonresectable alpha‐fetoprotein‐positive hepatoma

D. Ettinger, B. Epstein, S. Order, 1991, Cancer.

Computed tomography assisted volumetric analysis of primary liver tumor as a measure of response to therapy

D. Ettinger, E. Fishman, D S Ettinger, 1985, American journal of clinical oncology.

Multimodality cisplatin treatment in nonresectable afp positive hepatoma: Preliminary results

D. Ettinger, B. Epstein, S. Order, 1989 .

Radiolabeled iododeoxyuridine: safety evaluation.

M. Tempero, S. Cohen, J. Sharp, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The integration of tumor associated antigens in cancer management.

S. Leibel, M. Sgagias, S. Order, 1981, Seminars in Oncology.

Detection of specific anti-antibodies in patients treated with radiolabeled antibody.

J. Sandoz, S. Order, P. Leichner, 1986, International journal of radiation oncology, biology, physics.

An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy.

G T Chen, R J Jaszczak, K F Koral, 1993, Medical physics.

Distribution of and physiologic factors that affect 131I-antiferritin tumor localization in experimental hepatoma.

S. Order, P. Leichner, J. Klein, 1984, International journal of radiation oncology, biology, physics.

SPECT imaging of fluorine-18.

G V Dalrymple, H T Morgan, W. Hawkins, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The circular harmonic transform for SPECT reconstruction and boundary conditions on the Fourier transform of the sinogram.

N C Yang, W. Hawkins, P. Leichner, 1988, IEEE transactions on medical imaging.

Use of Isotopie Immunoglobulin in Therapy1

D. Ettinger, S. Siegelman, P. Alderson, 2006 .

Time dependence of the vacuum-uv emissions from neon, and energy transfers to the resonance statesNe(P11)andNe(P13)in helium-neon mixtures

P. Leichner, J. D. Cook, Stephen J. Luerman, 1975 .

Patient-specific dosimetry using quantitative SPECT imaging and three-dimensional discrete Fourier transform convolution.

W. Hawkins, G. Akabani, P. Leichner, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.